CUMBERLAND, R.I.– Neurotech Pharmaceuticals, Inc., a private biotechnology company focused on therapies for chronic eye diseases, announced that the Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-Code (J3403) to ENCELTO™ (revakinagene taroretcel-lwey), effective October 1, 2025. ENCELTO is the first and only FDA-approved treatment for idiopathic Macular Telangiectasia Type 2 (MacTel), a retinal disease that causes progressive vision loss.
J-codes are standardized reimbursement codes used by government and commercial insurers to facilitate billing for treatments administered by healthcare professionals. The assignment of a permanent J-code is intended to streamline claims processing, simplify reimbursement, and support broader patient access to ENCELTO.
“Receiving a permanent J-code in the U.S. supports our efforts to increase timely access to ENCELTO, the first and only FDA-approved treatment for MacTel,” said Richard Small, chief executive officer of Neurotech. “We are committed to making this important therapy available to patients in need.”
ENCELTO is based on Neurotech’s Encapsulated Cell Therapy (ECT), a first-in-class delivery platform designed to provide long-term, sustained release of therapeutic proteins for chronic eye conditions. The ECT capsule, containing genetically engineered cells, is surgically placed in the eye, where it delivers proteins directly to the retina while protecting the cells from the immune system to ensure continued function over time.
Neurotech’s first commercial product, ENCELTO, was approved in the United States for adults with MacTel, a bilateral, neurodegenerative retinal disease that leads to gradual vision loss and changes to the retinal vasculature.
